Hopp til hovedinnhold

Teriflunomid (Aubagio)

Sist oppdatert: Sist revidert:
Sist revidert av:
  1. Confavreux C, O'Connor P, Comi G, Freedman MS, Miller AE, Olsson TP, Wolinsky JS, Bagulho T, Delhay JL, Dukovic D, Truffinet P, Kappos L; TOWER Trial Group.. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial.. Lancet Neurol. 2014 ; Mar;13(3):: 247-56. pmid:24461574 PubMed  
  2. O'Connor P, Wolinsky JS, Confavreux C, Comi G, Kappos L, Olsson TP, Benzerdjeb H, Truffinet P, Wang L, Miller A, Freedman MS;. Randomized trial of oral teriflunomide for relapsing multiple sclerosis.. N Engl J Med 2011; 365: 1293-1303. pmid:21991951 PubMed  
  3. Radue E-W, Sprenger T, Gaetano L et al. Teriflunomide slows down brain volume loss in relapsing MS. A SIENA Analysis of the TEMSO MRI Dataset: Multiple Sclerosis Journal 2015, 23: (S11): 780-808
  4. He D, Zhang C, Zhao X, Zhang Y, Dai Q, Li Y, Chu L. Teriflunomide for multiple sclerosis. Cochrane Database Syst Rev. 2016 Mar 22;3:CD009882 . pmid:27003123 PubMed  
  5. Aubagio SPC 30.11.2018 Avsnitt 4.3
  6. O'Connor P, Comi G, Freedman MS, Miller AE, Kappos L, Bouchard JP, Lebrun-Frenay C, Mares J, Benamor M, Thangavelu K, Liang J, Truffinet P, Lawson VJ, Wolinsky JS; Teriflunomide Multiple Sclerosis Oral (TEMSO) Trial Group and the MRI-AC in Houston, Texas; Teriflunomide Multiple Sclerosis Oral TEMSO Trial Group and the MRI-AC in Houston Texas. Long-term safety and efficacy of teriflunomide: Nine-year follow-up of the randomized TEMSO study. Neurology. 2016 Mar 8;86(10):920-30 . pmid:26865517 PubMed  
  • Elisabeth Gulowsen Celius, spesialist i nevrologi, dr med
  • Unn Ljøstad, spesialist i nevrologi, professor PhD
  • Åse Mygland, spesialist i nevrologi, professor dr med